Why scientists and public health officials need to address vaccine mistrust instead of dismissing it

People who oppose vaccines often are dismissed as ignorant or naive. Failing to hear their concerns and address them may only be fueling vaccine resistance, however.

Porismita Borah, Associate Professor, health communication, Washington State University • conversation
Oct. 30, 2020 • ~10 min

How and when will we know that a COVID-19 vaccine is safe and effective?

Several vaccines are in Phase 3 trials. So when will we know whether any of these will protect against COVID-19?

William Petri, Professor of Medicine, University of Virginia • conversation
Sept. 22, 2020 • ~10 min

FDA is departing from long-standing procedures to deal with public health crises, and this may foreshadow problems for COVID-19 vaccines

The rushed emergency approval for a treatment that might help COVID-19 patients has raised questions: Is the FDA abandoning its own guidelines?

Yaniv Heled, Associate Professor of Law, Georgia State University • conversation
Aug. 27, 2020 • ~10 min

How to talk to vaccine skeptics so they might actually hear you

Those opposing vaccinations often mistrust government, science and the news media. There may be better ways to persuade them than by offering facts only.

Porismita Borah, Associate Professor, Washington State University • conversation
Aug. 20, 2020 • ~9 min

Here's how to talk to vaccine skeptics so they might actually hear you

Those opposing vaccinations often mistrust government, science and the news media. There may be better ways to persuade them than by offering facts only.

Porismita Borah, Associate Professor, Washington State University • conversation
Aug. 20, 2020 • ~9 min

A COVID-19 vaccine needs the public's trust – and it's risky to cut corners on clinical trials, as Russia is

As Russia fast tracks a coronavirus vaccine, scientists worry about skipped safety checks – and the potential fallout for trust in vaccines if something ends up going wrong.

Abram L. Wagner, Research Assistant Professor of Epidemiology, University of Michigan • conversation
Aug. 12, 2020 • ~7 min

Video: An infectious disease expert explains the results from Moderna's latest vaccine trials

The results from the phase 1 trial are a promising first step in showing that the mRNA vaccine is a viable candidate, but there are unanswered questions and it is still early in the process.

Sanjay Mishra, Project Coordinator & Staff Scientist, Vanderbilt University Medical Center, Vanderbilt University • conversation
July 17, 2020 • ~8 min

An infectious disease expert explains the results from Moderna's latest vaccine trials

The results from the phase 1 trial are a promising first step in showing that the mRNA vaccine is a viable candidate, but there are unanswered questions and it is still early in the process.

Sanjay Mishra, Project Coordinator & Staff Scientist, Vanderbilt University Medical Center, Vanderbilt University • conversation
July 17, 2020 • ~8 min

Ending the pandemic will take global access to COVID-19 treatment and vaccines – which means putting ethics before profits

The high cost of pharmaceuticals often means only the richest patients get lifesaving medicines. As coronavirus drugs emerge, it will require hard, creative work to ensure they're available to all.

Nicole Hassoun, Associate Professor of Philosophy, Binghamton University, State University of New York • conversation
July 16, 2020 • ~9 min

Cell-like decoys could mop up viruses in humans – including the one that causes COVID-19

Nanoparticles dressed up in cell membranes snag SARS-CoV-2 virus particles before they reach human cells.

Liangfang Zhang, Professor of Nanoengineering, University of California San Diego • conversation
July 9, 2020 • ~5 min

/

14